188宝金博页面版

DOI : １０． １３２１０ /j．cnki． jhmu． ２０１６０６０１． ００８网络出版地址:http :// www．cnki． net / kcms / detail / ４６． １０４９．R． ２０１６０６０１． １１４１． ０１６． html[基金项目]云南省应用基础研究(昆医联合专项)( ２０１３FB１７０ )[作者简介]朱家伦( １９７９Ｇ ),男,云南镇雄人,主治医师,电话: ０８７１６８１８７５３２ 、 １３７５９５１９１５９ , EＧmail : zhujl８８９６＠１６３．com .[收稿日期] ２０１６Ｇ０５Ｇ２３　　 [修回日期] ２０１６Ｇ０６Ｇ１１　　 网络出版时间: ２０１６Ｇ６Ｇ１１１ : ４１天晴依泰联合放射性药物 ８９ SrCl２ 治疗对肺癌骨转移病灶生长及临床症状的影响朱家伦 １ ,邓志勇 ２ ,杨传周 ３(昆明医科大学第三附属医院/云南省肿瘤医院核医学科,云南 昆明 。叮担埃保保 )　　 [摘要]目的:发现天晴依泰联合放射性药物 ８９ SrCl ２ 治疗对肺癌骨转移病灶生长及临床症状的影响.方法: １０２ 例肺癌骨转移患者纳入本次研究,根据接受的治疗方式不同,所有研究对象被随机分为观察组及对照组各 ５１ 例.对照组接受单独天晴依泰治疗,观察组接受天晴依泰联合放射性药物 ８９ SrCl２ 治疗,对比两组患者的肺癌骨转移病灶生长、骨代谢、肿瘤标志物及碱性磷酸酶、疼痛评分及疼痛相关介质等水平差异.结果:观察组治疗后转移灶数目少于对照组,血清 OPG 、 BSP 、 TRACPＧ５b 、ICTP 、 BAP 等骨代谢指标值,血清 CYFRA２１Ｇ１ 、 CEA 、 NSE 、 CA１２５ 、 BALP 等肿瘤标志物水平,血清 PGE２ 、 ETＧ１ 、TNFＧα 等疼痛相关介质水平均低于对照组( P ＜０． ０５ ).结论:天晴依泰联合放射性药物 ８９ SrCl ２ 治疗可以遏制肺癌骨转移病灶生长,在优化骨代谢状态的同时缓解患者疼痛感受.[关键词]肺癌骨转移;天晴依泰;８９ SrCl２[中图分类号] R７３４．２　 [文献标识码] A　 [文章编号] １００７Ｇ１２３７ ( ２０１６ ) １７Ｇ２００７Ｇ０４Effectsofzoledronicacidinjectioncombinedwithradiopharmaceutical８９SrCI２therapyonthegrowthandclinicalsymptomsoflungcancerbonemetastasisZHUJiaＧlun１ ,DENGZhiＧyong２ , YANGChuanＧzhou ３( DepartmentofNuclearMedicine , theThirdAffiliatedHospitalofKunmingMedicalUniversity / TumorHospitalofYunnanProvＧince , KunmingCity , YunnanProvince , ６５０１１８ )[FoundationProject ]: ThisstudywassupportedbyappliedbasicresearchprojectofYunnanProvince ( Kunmingmedicaljointproject , ２０１３ FB １７０ ) ．[ Author ]: ZHUJiaＧlun ( １９７９ Ｇ ), Male , XiongzhenYunnan , Attendingphysician , Tel : ０８７１６８１８７５３２ , １３７５９５１９１５９ , EＧmail : zhuＧjl８８９６ ＠ １６３． com ．Received : ２０１６ Ｇ ０５ Ｇ ２３　　 Revised : ２０１６ Ｇ ０６ Ｇ １１ JHMC , ２０１６ ; ２２ ( １７ ): ２００７ Ｇ ２０１０Viewfromspecialist : Itiscreative , andofcertainscientificandeducationalvalue．[ ABSTRACT ] Objective : Tofindtheeffectofzoledronicacidinjectioncombinedwithradiopharmaceutical８９SrCI２therapyonthegrowthandclinicalsymptomsoflungcancerbonemetastasis．Methods : １０２casesoflungcancerpatientswithbonemeＧtastaseswereincludedinthestudyandrandomlydividedintoobservationgroupandcontrolgroup ( n ＝５１ ) accordingtodifferＧenttreatmenttheyreceived．Controlgroupreceivedzoledronicacidinjectiontherapyalone , observationgroupreceivedzoledronＧicacidinjectioncombinedwithradiopharmaceutical８９SrCI２therapy , andthendifferencesinthegrowthoflungcancerbonemetastasis , bonemetabolism , tumormarkersandalkalinephosphatase , painscoreandpainＧrelatedmediatorlevels , etc．werecomparedbetweentwogroups．Results : NumberofmetastasesofobservationgroupaftertreatmentwaslessthanthatofconＧtrolgroup , andserumbonemetabolismindexesOPG , BSP , TRACPＧ５b, ICTPandBAPlevels , serumtumormarkersCYＧFRA２１Ｇ１ , CEA , NSE , CA１２５andBALPlevelsaswellasserumpainＧrelatedmediatorsPGE２ , ETＧ１andTNFＧαlevelswerelowerthanthoseofcontrolgroup ( P ＜０． ０５ ) ．Conclusion : Zoledronicacidinjectioncombinedwithradiopharmaceutical８９SrCI２therapycancontainthegrowthoflungcancerbonemetastasis , optimizebonemetabolismstatewhilealleviatepatients＇percepＧ７ ０ ０ ２海南医学院学报 。玻埃保 , ２２ ( １７ )JournalofHainanMedicalUniversity